Sensinel Cardiopulmonary Management (CPM) System
Analog Devices · Decision date Oct 16, 2026
What did the FDA decide?
The FDA recorded a substantially equivalent (SESE) decision on 16 October 2026 for the Sensinel Cardiopulmonary Management (CPM) System, submitted by Analog Devices of Wilmington, Massachusetts, under 510(k) number K260801. The application was received on 11 March 2026 and reviewed through the traditional pathway by the Cardiovascular panel; the agency lists it as not reviewed by a third party, not a combination product, and without an authorized predetermined change control plan. SESE denotes 510(k) clearance rather than PMA approval.
The listed classification is product code MWI, regulation 870.2300, physiological patient monitor without arrhythmia detection or alarms, with subsequent product codes BZQ, DPS, DQD, DSB, DXH and FLL. The record does not identify which components or modifications were assessed, the predicates cited, or any performance data, so the basis for the equivalence finding and the cleared indications remain unknown from this page.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 16, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K260801
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Analog Devices
- Product code
- MWI
- Decision code
- SESE
- Decision date
- Oct 16, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Monitor, Physiological, Patient (Without Arrhythmia Detection Or Alarms).
- Applicant
- Analog Devices
- Product code
- MWI
- FDA device class
- 2
FDA decision timeline
K260801 received
Application receipt date recorded by FDA.
K260801 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code MWI
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Vital Signs Monitor (CLEO2)K260438 | Infinium Medical, Inc. | 510(k) clearance | Aug 14, 2026 | FDA |
| Masimo Corporation | 510(k) clearance | Aug 12, 2026 | FDA | |
BioTracker 2.0K253306 | Biotracker, LLC | 510(k) clearance | Jun 26, 2026 | FDA |
| Midmark Corporation | 510(k) clearance | Jun 12, 2026 | FDA | |
c-med0 alphaK253436 | Cosinuss GmbH | 510(k) clearance | Apr 30, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Analog Devices
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Wilmington, MA
Sources and methodology
- Original FDA record: K260801
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



